Glidiab
Glidiab: instructions for use and reviews
- 1. Release form and composition
- 2. Pharmacological properties
- 3. Indications for use
- 4. Contraindications
- 5. Method of application and dosage
- 6. Side effects
- 7. Overdose
- 8. Special instructions
- 9. Application during pregnancy and lactation
- 10. Use in childhood
- 11. In case of impaired renal function
- 12. For violations of liver function
- 13. Use in the elderly
- 14. Drug interactions
- 15. Analogs
- 16. Terms and conditions of storage
- 17. Terms of dispensing from pharmacies
- 18. Reviews
- 19. Price in pharmacies
Latin name: Glidiab
ATX code: A10BB09
Active ingredient: gliclazide (gliclazide)
Manufacturer: Akrikhin, JSC (Russia)
Description and photo update: 2019-26-08
Prices in pharmacies: from 100 rubles.
Buy
Glidiab is a II generation sulfonylurea derivative, oral hypoglycemic drug.
Release form and composition
Dosage form - tablets: flat-cylindrical, white or white with a cream or yellowish tint, with a bevel (10 pcs. In blister packs, 6 packs in a cardboard box).
Active ingredient: gliclazide, 1 tablet - 80 mg.
Additional components: hypromellose, potato starch, sodium carboxymethyl starch, talc, lactose monohydrate, magnesium stearate, microcrystalline cellulose.
Pharmacological properties
Pharmacodynamics
The active ingredient of Glidiab is gliclazide, a second generation sulfonylurea derivative, an oral hypoglycemic agent.
The mechanism of action of gliclazide is due to its ability to stimulate the secretion of insulin by the beta cells of the pancreas, potentiate the insulin-secretory effect of glucose and increase the sensitivity of peripheral tissues to insulin. Also, the drug stimulates the activity of intracellular enzymes of muscle glycogen synthetase. Reduces postprandial rise in glucose levels. Restores the early peak of insulin secretion (unlike other sulfonylurea derivatives, which act mainly during the second phase of secretion). Reduces the time interval from the moment of eating to the beginning of insulin secretion.
In addition to the effect on carbohydrate metabolism, gliclazide improves microcirculation: it normalizes vascular permeability, reduces platelet aggregation and adhesion, restores the process of physiological parietal fibrinolysis, and prevents the development of atherosclerosis and microthrombosis. Reduces the sensitivity of blood vessels to adrenaline.
Glidiab slows down the development of diabetic retinopathy in the non-proliferative stage. With diabetic nephropathy, in the case of prolonged use of the drug, a significant decrease in proteinuria is noted.
Gliclazide acts mainly on the early peak of insulin secretion, does not cause hyperinsulinemia, and therefore does not lead to an increase in body weight. On the contrary, with an appropriate diet, it helps to reduce body weight in obese patients.
Pharmacokinetics
After taking Glidiab inside, the active substance is absorbed in the gastrointestinal tract. Gliclazide is characterized by a high degree of absorption. After a single dose of 80 mg, the maximum concentration in the blood (C max) is observed after about 4 hours and is 2.2-8 μg / ml, with a single dose of 40 mg, C max is reached after about 2-3 hours and is 2-3 μg / ml.
Gliclazide binds to plasma proteins by 85–97%. The volume of distribution is 0.35 l / kg. Equilibrium concentration is reached on the second day.
The drug is metabolized in the liver, resulting in the formation of 8 metabolites. The main metabolite (2-3% of the dose) does not have hypoglycemic activity, but improves microcirculation.
The half-life can last from 8 to 20 hours.
The drug is excreted mainly by the kidneys (70% - in the form of metabolites, less than 1% - unchanged), as well as with feces (12% - in the form of metabolites).
Indications for use
According to the instructions, Glidiab is a drug for the treatment of non-insulin dependent diabetes mellitus (type 2). It is used in combination with diet therapy and moderate physical activity when they are ineffective as the main means of combating the disease.
Contraindications
Absolute:
- Insulin-dependent diabetes mellitus (type 1);
- Diabetic ketoacidosis, precoma, and coma;
- Hyperosmolar coma;
- Severe renal / hepatic impairment;
- Conditions accompanied by impaired absorption of food and the development of hypoglycemia (including gastric paresis, intestinal obstruction, infectious diseases);
- Leukopenia;
- Conditions that require insulin therapy, including trauma, extensive burns, and surgery;
- Pregnancy and lactation;
- Individual hypersensitivity to drug components.
Glidiab tablets should be used with caution in diseases of the thyroid gland, accompanied by a violation of its function, with alcoholism, febrile syndrome.
Instructions for the use of Glidiab: method and dosage
Glidiab tablets should be taken orally 30-60 minutes before meals 2 times a day, morning and evening.
Doses are selected individually for each patient, depending on his age, as well as clinical manifestations of the disease and the level of glycemia, determined on an empty stomach and 2 hours after eating.
At the beginning of therapy, 80 mg is prescribed per day. The average therapeutic daily dose is 160 mg, the maximum allowable is 320 mg.
Side effects
- Endocrine system: hypoglycemia (with inadequate diet and violation of the dosage regimen) - irritability, anxiety, inattention, aggressiveness, inability to concentrate, delayed reaction, severe weakness, depression, fatigue, headache, tremor, aphasia, dizziness, feeling of helplessness, visual impairment, loss of self-control, hypersomnia, sensory disorders, hunger, loss of consciousness, seizures, sweating, shallow breathing, delirium, bradycardia;
- Digestive system: dyspepsia (feeling of heaviness in the epigastrium, diarrhea, nausea), abnormal liver function (increased activity of hepatic transaminases, cholestatic jaundice), anorexia (its severity decreases when the drug is taken with meals);
- Hematopoietic system: thrombocytopenia, anemia, leukopenia;
- Allergic reactions: urticaria, itching, maculopapular rash.
Overdose
In case of an overdose of Glidiab, hypoglycemia may develop, up to hypoglycemic coma.
If the patient is awake, a sugar solution or glucose (dextrose) should be taken orally. In case of loss of consciousness, a solution of dextrose 40% is administered intravenously and glucagon (1-2 ml) is administered intramuscularly. After the restoration of consciousness, in order to avoid the recurrence of hypoglycemia, the patient should be given food rich in easily digestible carbohydrates.
special instructions
A low-calorie, low-carbohydrate diet is a prerequisite for successful Glidiab treatment.
During therapy, it is necessary to regularly monitor the level of fasting blood glucose and after meals.
Patients should keep in mind that fasting, drinking alcoholic beverages and taking nonsteroidal anti-inflammatory drugs are risk factors for the development of hypoglycemia. In addition, when alcohol is taken, a disulfiram-like reaction may develop, manifested by abdominal pain, headache, nausea and vomiting.
The elderly and weakened people are especially sensitive to the action of hypoglycemic drugs, and patients who do not receive a balanced diet and suffer from pituitary-adrenal insufficiency.
Changes in diet, emotional or physical stress may require dose adjustment of Glidiab.
With decompensation of diabetes mellitus and the need for surgical interventions, a temporary transfer of the patient to insulin may be required.
Influence on the ability to drive vehicles and complex mechanisms
Patients prone to the development of hypoglycemia are advised to refrain from engaging in potentially hazardous activities that require speed of reactions and increased attention, including driving vehicles, during the dose selection period.
Application during pregnancy and lactation
Glidiab is prohibited for use during pregnancy.
If treatment is required for lactating women, breastfeeding should be discontinued.
Pediatric use
The efficacy and safety of gliclazide when taken in childhood has not been established, therefore, the drug is not prescribed for patients under 18 years of age.
With impaired renal function
Glidiab is contraindicated in severe renal failure.
For violations of liver function
Glidiab is contraindicated in severe liver failure.
Use in the elderly
The drug should be used with caution, since elderly patients are more sensitive to the action of hypoglycemic drugs.
Drug interactions
With the simultaneous use of the following drugs, an increase in the hypoglycemic effect of Glidiab is noted: angiotensin-converting enzyme inhibitors (enalapril, captopril), histamine H 2 blockers-receptors (cimetidine), non-steroidal anti-inflammatory drugs (indomethacin, phenylbutazone, diclofenac), antifungal drugs (fluconazole, miconazole), anti-tuberculosis drugs (ethionamide), beta-adrenergic blockers, indirect anticoagulants, coumarinic acid, cumibratibarine monoamine oxidase inhibitors, long-acting sulfonamides, tubular secretion blocking drugs, salicylates, pentoxifylline, fluoxetine, fenfluramine, chloramphenicol, cyclophosphamide, theophylline, guanethidine, reserpine, disopyramide, allopuridin, other drugs and ethanol-containing agents.
With the simultaneous use of the following drugs, there is a decrease in the hypoglycemic effect of Glidiab: barbiturates, glucocorticosteroids, slow calcium channel blockers, thiazide diuretics, sympathomimetics (clonidine, epinephrine, ritodrin, terbutaline, salbutamol), carbonic anhydrase inhibitors, acetazolamides, estrogens, estrogens contraceptives, phenytoin, triamterene, furosemide, baclofen, isoniazid, diazoxide, danazol, asparaginase, chlorthalidone, glucagon, morphine, rifampicin, lithium salts, high-dose nicotinic acid, chlorpromazine.
Reserpine, clonidine, guanethidine and beta-blockers can mask the clinical manifestations of hypoglycemia.
In patients receiving cardiac glycosides, Glidiab increases the risk of developing ventricular premature beats.
When gliclazide interacts with ethanol, a disulfiram-like reaction may develop.
Analogs
Glidiab analogs are: Glemaz, Amaryl, Glyri, Amix, Glybetik, Diabrex, Glianov, Maninil, Glibenclamide, Diameprid, Glimepirid, Diapirid, Glinova, Meglimid, Glurenorm, Oltar, Eglim Diabeton, Glidiab MV, MV, MV, MV, Gliclazide MB, Diagliside MB, Gluktam, Diabinax, Glucostabil, Diatica, Glioral, Diabresid, Osiklid.
Terms and conditions of storage
Store at temperatures up to 25 ° C in a dry, dark place out of reach of children.
Shelf life is 4 years.
Terms of dispensing from pharmacies
Dispensed by prescription.
Reviews about Glidiab
Reviews about Glidiab on various thematic forums and sites are few, but mostly positive. Patients note that the drug is very effective, it regulates the glucose level between meals well, eliminates the negative manifestations of non-insulin dependent diabetes, and practically has no side effects. However, as with any other similar medicines, to achieve a good effect, you must adhere to an appropriate diet and follow the recommendations for exercise.
The cost of Glidiab is estimated to be affordable.
Price for Glidiab in pharmacies
The approximate price of Glidiab is 109-144 rubles. per pack of 60 tablets of 80 mg.
Glidiab: prices in online pharmacies
|
Drug name Price Pharmacy |
|
Glidiab 80 mg tablets 60 pcs. RUB 100 Buy |
|
Glidiab MV 30 mg modified release tablets 60 pcs. 112 RUB Buy |
|
Glidiab tablets 80mg 60 pcs. 129 RUB Buy |
Anna Kozlova Medical journalist About the author
Education: Rostov State Medical University, specialty "General Medicine".
Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!
